INDV · XBRL financial data

Indivior Pharmaceuticals financial statements, every fiscal year

The same tables from 3 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (INDV's year ends in late December)

In millions of dollars	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue from contracts with customers	1,093	1,188	1,239
Cost of goods and services sold	174	231	246
Gross profit	919	957	994
Selling, general and administrative	565	618	634
Total operating expenses	1,072	925	—
Operating income (loss)	(152)	32	262
Interest income	43	23	22
Interest expense	35	41	45
Income tax expense (benefit)	(19)	11	29
Net income (loss)	(126)	2	210
Earnings per share, basic USD per share	(0.92)	0.02	1.68
Earnings per share, diluted USD per share	(0.92)	0.02	1.64
Weighted average shares, basic millions of shares	137	132	125
Weighted average shares, diluted millions of shares	137	133	128
Cost of sales	186	—	—
Gross profit	907	—	—
Research and development	106	—	—
Operating profit (loss)	(4)	—	—
Profit (loss)	2	—	—

Fiscal years (INDV's year ends in late December)

In millions of dollars	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	316	319	195
Short-term investments	94	1	0
Accounts receivable	254	254	253
Inventory	126	178	153
Prepaid and other current assets	52	53	—
Total current assets	1,257	839	652
Property and equipment, net	84	100	144
Right-of-use asset	40	39	26
Goodwill	5	2	2
Total assets	1,758	1,319	1,201
Accounts payable	39	63	48
Current portion of long-term debt	3	18	29
Total current liabilities	1,281	939	914
Long-term debt	237	315	290
Lease liability, non-current	34	32	22
Total liabilities	1,942	1,668	1,300
Accumulated deficit	(288)	(454)	(243)
Total stockholders' equity	(184)	(348)	(98)
Total liabilities and equity	1,758	1,319	1,201
Common shares outstanding (cover page) millions of shares	137	125	125
Cash and cash equivalents	316	—	—
Total current assets	1,263	—	—
Total assets	1,954	—	—
Total current liabilities	1,305	—	—
Total liabilities	1,954	—	—
Total equity	0	—	—

Fiscal years (INDV's year ends in late December)

In millions of dollars	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(126)	2	210
Stock-based compensation	21	24	26
Depreciation and amortization	15	29	10
Net cash from operating activities	(300)	36	(27)
Purchases of property and equipment	8	29	66
Net cash from investing activities	(95)	69	(66)
Proceeds from issuing common stock	3	3	2
Share repurchases	33	173	11
Proceeds from long-term debt	0	332	0
Repayments of long-term debt	12	240	17
Net cash from financing activities	(64)	(102)	(30)
Net cash from operating activities	(315)	—	—
Net cash from investing activities	(98)	—	—
Net cash from financing activities	(46)	—	—

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Runway	Quarter
Indivior Pharmaceuticals	305	356	97*	118.0M	—	Q3 FY26 10-QSep 30, 2026
Apellis Pharmaceuticals	405	268	(61)	128.0M	6.6 quarters	Q1 FY26 10-QMar 31, 2026
Biocryst Pharmaceuticals	155	not reported	104*	255.5M	—	Q2 FY26 10-QJun 30, 2026
Agios Pharmaceuticals	100	45	(57)*	59.7M	10.8 quarters	Q2 FY26 10-QJun 30, 2026
Amicus Therapeutics	214	185*	16*	314.0M	—	Q4 FY25 10-KDec 31, 2025
Supernus Pharmaceuticals	176	227	6.6*	58.2M	—	Q3 FY26 10-QSep 30, 2026
Sarepta Therapeutics	571	401	197*	105.6M	—	Q2 FY26 10-QJun 30, 2026
Bausch Health Companies	2,485	2,941	814*	374.3M	—	Q3 FY26 10-QSep 30, 2026
Recursion Pharmaceuticals	550	19	(77)*	622.8M	6.2 quarters	Q3 FY26 10-QSep 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.